Background and Objectives: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a
multifunctional natural matrixin inhibitor that is generally considered a negative regulator of
cancer metastasis. Clinical studies reporting the prognostic value of TIMP-1 in non-small cell
lung cancer (NSCLC) are inconsistent. Therefore, the present study aimed to determine the
prognostic impact of TIMP-1 expression in NSCLC.
Methods: Appropriate studies with full-text articles were identified in searches of the China
National Knowledge Infrastructure (CNKI), Cochrane Library, PubMed, and Web of Science
databases up to March 7, 2018. The pooled hazard ratio (HR) of overall survival with a 95%
confidence interval (95% CI) was employed to assess the relationship between the expression
of TIMP-1 and NSCLC patient survival.
Results: The meta-analysis comprised 40 studies including 3,194 patients. Study outcomes
indicated that high TIMP-1 expression is independently associated with poor overall survival
(HR: 1.60; 95% CI: 1.50, 1.69; P < 0.00001) with 61% of heterogeneity. In addition, we analyzed
subgroups, including ethnicities, histological types, percentage of TIMP-1 expression
levels, specimens, and tumor stage. All results were statistically significant. The outcome of
our meta-analysis indicates that high expression levels of TIMP-1 are correlated with poor
prognosis in patients with NSCLC.
Conclusion: Expression levels of TIMP-1 represent a potential prognostic biomarker in
NSCLC patients in addition to being a possible therapeutic target.
Keywords: antiapoptosis, cell proliferation, IHC, meta-analysis, non-small cell lung cancer, tumor invasion, tissue inhibitor of metalloproteinase-1.
Rights & PermissionsPrintExport